MabVax Therapeutics Holdings Inc

MabVax Therapeutics — Investor Presentation (June 2017)

23 slides from MabVax Therapeutics's investor presentation, Jun 23, 2017

  1. Slide 1: MabVax Therapeutics Corporate Presentation June 2017

    Slide 1: MabVax Therapeutics Corporate Presentation June 2017

    \y/ MabVax therapeutics Corporate Presentation June 2017 NASDAQ: MBVX ‘wirenabvatlae

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements and projections. The company makes no express or implied representation or warranty as to the completeness of this information or, inthe case of the projections, as to their attainabilty or the accuracy and completeness

  3. Slide 3: Table of Contents

    Slide 3: Table of Contents

    M Table of Contents + Company Overview + Management Team & Board of Directors * Discovery Platform + Pipeline + Safety & Efficacy Data + Development Plan * Corporate

  4. Slide 4: Company Overview

    Slide 4: Company Overview

    Company Overview Fully-Human Antibody | | MabVaxis an antibody discovery and development company with products that were Discovery Platform | discovered from the immune response of cancer patients Clinical stage Developmant Company | | Thee active Phase 1 clinica rials targeting CA19-9 positive mali

  5. Slide 5: Management Team

    Slide 5: Management Team

    Management Team J. David Hansen _ ; AVANIER Schering Pu feo shes Sub President, ceO and Chairman «AN AWM, DUT B® f “Gregory . Hanson, CMA, MBA piece MAST Chief Financial Otficer = Philip 0. Livingston, M.D. Chief Scientific officer anes apmn AAIPHARMA EM ARENA & Wand chet Busnes oficer — JSventat in

  6. Slide 6: Board of Directors

    Slide 6: Board of Directors

    Board of Directors Mi J, David Hansen President, CEO and Chairman of MabVax Jeffrey F. Eisenberg Former CEO Noven Pharmaceuticals, Former Acting Gen Counsel IVAX Jeffrey V. Ravetch, M.D., Ph.D. National Academy of Sciences and Institute of Medicine, Academy of Arts and Sciences and the American Asso

  7. Slide 7: Human Antibody (HuMab) Discovery Platform

    Slide 7: Human Antibody (HuMab) Discovery Platform

    Human Antibody (HuMab) Discovery Platform Proprietary Approach to the Discovery and Development of Novel Fully Human Antibody Therapy and Diagnostic Agents Focused Discovery Screening Optimized Therapy Fully human antibody ‘minimizes immunogenicity. Binding sequence reflects the patient's immune sys

  8. Slide 8: Scientific Rationale

    Slide 8: Scientific Rationale

    \ ’ { Scientific Rationa Say Lewis (te), the Hua 561 tara, isexgrezedin over 90% of panereate snd + CA19 91s considered a vatable adjnctn the diagnos, prognosis and montoring of + steis densely expressed in mits of opy numbers on toget umors ae ae ee) [A Pancreatic; 8 Colon. Lung. Blader © ovanan; B

  9. Slide 9: Radioimmunotherapy (RIT) is Lead Clinical Program

    Slide 9: Radioimmunotherapy (RIT) is Lead Clinical Program

    Radioimmunotherapy (RIT) is Lead Clinical Program Mi Antibody-Based Therapeutic Agent to Treat Very Difficult Cancers Such as Pancreatic, Small Cell Lung and Colon + Target significantly over, expressed on cancers « Antibody has high degree of Established safety, specifiy, specificity for tumors. ‘a

  10. Slide 10: Pipeline

    Slide 10: Pipeline

    Vi Se Protram Discovery Lead Op__PresND__Phasex_——__Phase2 ‘SialylLewis*for Pancreatic Cancer and CA19-9 malignancies including Lung and Gl Cancers Radioimmunotherapy (MVT1075) a Therapeutic (MVT-5873): Monotherapy > ‘Therapeutic (MVT-5873): + Chemo —SEEEESSS ImmunoPET imaging (MVT-2163) SEE Ta for

  11. Slide 11: Safety and Efficacy

    Slide 11: Safety and Efficacy

    Safety and Efficacy

  12. Slide 12: ing of transient elev

    Slide 12: ing of transient elev

    ing of transient elev typically resolved within a week ions in ALT, AST and rubin that Infusion reactions were mitigated with pre-medication and extended infusion times The MTD was established at 1 mg/kg + Al (1mg/kg) dosed every second week ue Bee Be ‘Ad (1me/ke) dosed every week Clears use in comb

  13. Slide 13: Inclusion Criteria Established for Future Clinical Trials

    Slide 13: Inclusion Criteria Established for Future Clinical Trials

    M Inclusion Criteria Established for Future Clinical Trials * Phase 1a identified “responder subset” with at least 50% reduction in CA19-9 levels after single agent treatment. The “responder subset”: Are patients at screening that had CA19-9 levels < 2500 U/mL Stayed on treatment 4 months versus 1 m

  14. Slide 14: Scientific and Medical Rationale for Imaging and RIT Dosing Strategy

    Slide 14: Scientific and Medical Rationale for Imaging and RIT Dosing Strategy

    M Scientific and Medical Rationale for Imaging and RIT Dosing Strategy + Antibodies are processed in the liver and spleen which play a central role in antibody clearance + Administration of cold antibody first saturates clearance mechanisms and reduces accumulation in liver and spleen + Cold-Hot dos

  15. Slide 15: Cold-Hot Dosing Strategy Reduces Liver and Spleen Accumulation

    Slide 15: Cold-Hot Dosing Strategy Reduces Liver and Spleen Accumulation

    Cold-Hot Dosing Strategy Reduces Liver and Spleen Accumulation Mi Data Support Using the Cold-Hot Dosing Strategy for RIT Program MiP images of two patients illustrating decreased liver SUV after cold pre-dose at day 7 2 Sx Sow EY Cencerttonatepcetin § 104 ne & 0 #17 «47 re IL . u dpe verre ener SUV

  16. Slide 16: HuMab-5B1 Specifically Targets CA19-9 Positive Tumor Lesions

    Slide 16: HuMab-5B1 Specifically Targets CA19-9 Positive Tumor Lesions

    HuMab-5B1 Specifically Targets CA19-9 Positive Tumor Lesions Focal radiotracer uptake above background was observed in primary tumors and metastases from day 2 and continuously increased through day 7 + Day 7 tumor SUV,,,, Were as high as 101 g/mL FOG PET SUV, values “10 g/mL. + High focal uptake wa

  17. Slide 17: Clinical Development Plan of Lead Asset MVT-1075 (RIT)

    Slide 17: Clinical Development Plan of Lead Asset MVT-1075 (RIT)

    Clinical Development Plan of Lead Asset MVT-1075 (RIT)

  18. Slide 18: One Cycle of Treatment

    Slide 18: One Cycle of Treatment

    ) One Cycle of Treatment Day 1 * MVT-5873 Cold Dose # ~Ahours wait Day 15 * MVT-1075 Hot Dose Day 57 Safety monitoring visits throughout and dosimetry completed day 8 RIT (MVT-1075) Phase 1a Clinical Trial First-In-Human Phase 1 + Nonrandomized, open-label, dose- escalation (343 <esign) cohort expan

  19. Slide 19: RIT (MVT-1075) Phase 1 Trial 2017

    Slide 19: RIT (MVT-1075) Phase 1 Trial 2017

    RIT (MVT-1075) Phase 1 Trial 2017 + Firstin-Human dose June 2017 + Primary Objectives + ive inden aes aa ole ret Determine the MTD and safety profile of MVT-S873 / MVT-1075 Honor Health (niated) and MSKCC (planned early 3) * Secondary Objectives: «+ Enroll ~6 patients in 2017 Evaluate tumor response

  20. Slide 20: Financial and IP Snapshot

    Slide 20: Financial and IP Snapshot

    Mi NASDAQ Share Price* Market Cap* 3M Avg, Daily Volume* Common Stock Outstanding Preferred Stock {common equivalents with voting backer) Public Float Cash as of March 31, 2017! PIPE/Offering, net, May 2017 Financial and IP Snapshot MBVx $1.47 $12.8M 80.0K 87M 6.0M 83M $ 06M $ 43M + Key clinical ass

  21. Slide 21: Milestones and News Flow

    Slide 21: Milestones and News Flow

    Milestones and News Flow | herapy| {Pree @aacr | Fle orphan Org | Interim softy & Phose 10 MTD Radioimmunotherapy | 7 pases bose Designation ‘hear AACR 0 ASCO Single Agent 7 Phase 1a @ ASCO ‘AACRNCLEORTE Chemo Combination Inter Safety AACRNCEORTE PET Imaging Agent HuMab-581 Fe Phage 10.6 SNM = ‘Aree

  22. Slide 22: Radioimmunotherapy (MVT-1075) program guided by recent clinical experience

    Slide 22: Radioimmunotherapy (MVT-1075) program guided by recent clinical experience

    dS * Radioimmunotherapy (MVT-1075) program guided by recent clinical experience 50 patients in three active clinical investigations with the HuMab-5B1 Antibody Data from completion of two Phase 1 studies accelerates RIT program * Significant unmet medical need in cancers with poor prognosis + Large

  23. Slide 23: MabVax Therapeutics

    Slide 23: MabVax Therapeutics

    MabVa» therapeutics NASDAQ: MBVX ‘wirenabvatlae

Source: SEC EDGAR · 8-K filed Jun 23, 2017

More decks from MabVax Therapeutics Holdings Inc